Comparative Effectiveness of Ranolazine and Saroglitazar on Non Alcoholic Fatty Liver Disease in Patients with Diabetic Dyslipidemia A Randomised Controlled Open Label Trial

Abstract

Non-alcoholic fatty liver disease (NAFLD) will be the principal reason for newlineongoing liver sickness of nations in west by 2030, and liver transplantation will become newlinemore widespread as a result. A common misconception about fatty liver is that it is the newlinehepatic aspect of metabolic syndrome because it is associated with insulin resistance (IR) newlineand dyslipidemia. Fatty liver is linked to Type 2 Diabetes Mellitus (T2DM) and is seen newlinein 70-80% of T2DM patients. Due to the lack of a standard treatment for NAFLD, current newlinetherapeutic techniques focus on treating diabetic dyslipidemia newline